Casein Glycomacropeptide in Active Distal Ulcerative Colitis (Pilot Study)
Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
Casein glycomacropeptide (CGMP) has anti-inflammatory properties in experimental rodent
colitis and using human in vitro inflammation models. Its use as a food ingredient has proven
safe and with no influence on dietary intake. We hypothesize that orally administered CGMP
has a beneficial effect comparable to that of mesalazine in active distal ulcerative colitis.